mp.weixin.qq.com· 同写意·· 2026-09-14PickScore69
B7-H3 ADC Tam-Peli Cuts Death Risk 54% in Relapsed Small Cell Lung Cancer Phase III Trial
B7-H3靶点ADC率先突破——宜联生物改写小细胞肺癌二线治疗格局
In brief
The B7-H3-targeted ADC Tam-Peli (YL201) improved overall survival, progression-free survival and objective response rate in patients with relapsed small cell lung cancer versus topotecan hydrochloride, according to phase III TAISHAN-302 data presented at WCLC. The drug reduced the risk of death by 54% and the risk of disease progression or death by 71%. The results position the first B7-H3 ADC to break through in second-line treatment of this disease.
Why it matters
First phase III readout for a B7-H3 ADC in relapsed small cell lung cancer, with large survival gains over standard topotecan.
Source: mp.weixin.qq.com · mp.weixin.qq.com